placeUnited Kingdom
Contact & Support
Medtronic / Covidien Products / Multiparameter Monitoring / New! RespArray™ patient monitor

You are entering HCP content only

Please note you are entering now content intended only for Healthcare Professionals.

Are you a HCP?

Intuitive Multiparameter Patient Monitoring

Patient safety made simple

97%1 of postoperative opioid-induced respiratory depression is likely preventable with better continuous monitoring and response.

Staffing shortages can make it challenging to check on your patients as often as you’d like.

But what if you could monitor patients from anywhere in the hospital? Now you can, with RespArray™, your multiparameter patient monitor.

It’s designed for areas of care where spot checking might not be enough, like in medical-surgical units, or where additional parameters are needed, such as capnography in procedural sedation. Helping you detect respiratory compromise early and intervene sooner. 2,3,4

Monitor five parameters:

Are you interested in the new RespArray™ monitor or a free demo?

Please complete this form and we will contact you as soon as possible.

Learn about the benefits of Resparray in just 2 minutes! Watch Video:

Benefits of Resparray™, the multiparameter patient monitor

Remote patient monitoring

Problem

On average, medical-surgical registered nurses spend 96% of their shift away from the patient's bedside.5

Solution

The RespArray™ patient monitor features simple connectivity and seamlessly integrates into workflow. So you’ll have more time to focus on your patients

Features

  • Connection to EMR and VitalSync™ remote patient monitoring system†
  • Includes SpO2 (Nellcor™ pulse oximetry) and etCO2 (Microstream™ capnography) proprietary algorithms, plus ECG, NiBP, and continuous temperature monitoring.
  • HL7 interface
  • Large, intuitive touchscreen visible from multiple angles and distances

Manage risks - and alarms 

Alarm solution

The Smart Alarm for Respiratory Analysis™ (SARA) in Microstream™ technology reduces unneccessary nuisance alarms by 55%.6

Manage risks 

Experience world-class Nellcor™ pulse oximetry and Microstream™ capnography technologies, designed to help you detect respiratory compromise early7,8 — and help reduce insignificant alarms9.

Contact us

Are you interested in the new RespArray™ monitor or a free demo?

Please complete this form and we will contact you as soon as possible.

 

The measurements provided through the RespArray™ patient monitor, including Nellcor™, Microstream™, and other vital signs, should not be used as the sole basis for diagnosis or therapy and are intended only as adjuncts to patient assessment.

Resources

  • † This assumes a 20% respiratory depression reduction and an annual general care floor volume of 2,447 patients receiving opioids per median-sized hospital. 90% of surgical patients and 45% of medical patients on U.S. general care floors receive opioids. Continuous pulse oximetry and capnography device pricing assumptions used list pricing for the following: a Capnostream™ 35 portable respiratory monitor prorated over 7 years; a Microstream™ capnography filter line, and a disposable Nellcor™ pulse oximetry sensor, resulting in $52.73 in device costs per continuously monitored patient stay on a medical surgical floor. For intermittent pulse oximetry monitoring, device pricing consisted of a multiparameter monitor prorated over 7 years and a reusable pulse oximetry sensor, resulting in $0.68 in device costs per patient stay. Additional information on pricing and assumptions are available in the study publication.
  • 1. Richard D. Urman, Ashish K. Khanna, Sergio D. Bergese, Wolfgang Buhre, Maria Wittmann, Morgan Le Guen, Frank J. Overdyk, Fabio Di Piazza, Leif Saager, Postoperative opioid administration characteristics associated with opioid-induced respiratory depression: Results from the PRODIGY trial, Journal of Clinical Anesthesia, Volume 70, 2021, 110167
  • 2. Cacho G, Pérez-Calle JL, BarbadoA, LledóJL, OjeaR, Fernández Rodríguez CM. Capnography is superior to pulse oximetry for the detection of respiratory depression during colonoscopy. Rev EspEnferm Dig. 2010 Feb;102(2):86-9.
  • 3. Hutchison R, Rodriguez L. Capnography and respiratory depression. Am J Nurs. 2008 Feb;108(2):35-9
  • 4. Peveling-Oberhag J, Florian M, Tal A, Welsch C, Vermehren J, Farnik H, Grammatikos G, Lange C, Walter D, Blumenstein I, Filmann N, Herrmann E, Albert J, Zeuzem S, Bojungaand J, Friedrich-Rust M. Capnography monitoring of non-anesthesiologist provided sedation during percutaneous endoscopic gastrostomy placement: A prospective, controlled, randomized trial. Journal of Gastroenterology and Hepatology 35 (2020) 401–407
  • 5. Hendrich A, Chow MP, Skierczynski BA, Lu Z. A 36-hospital time and motion study: how do medical-surgical nurses spend their time? Perm J. 2008 Summer;12(3):25-34. doi: 10.7812/tpp/08-021. PMID: 21331207; PMCID: PMC3037121.
  • 6. Colman J, Cohen J, Lain D. Smart alarm respiratory analysis (SARA) used in capnography to reduce alarms during spontaneous breathing. Supplement to ANESTH ANALG, April 2008, Volume 106, No. 4S, Abstract S-10. – also in brochure
  • 7. Maddox R, Williams CK, Oglesby H, et al. Clinical experience with patient controlled analgesia using continuous respiratory monitoring and a smart infusion system. Am J Health Syst Pharm. 2006;63(2):157-164.
  • 8. Chung F, Wong J, Mestek ML, Niebel KH, Lichtenthal P. Characterization of respiratory compromise and the potential clinical utility of capnography in the post-anesthesia care unit: a blinded observational trial. J Clin Monit Comput. June 2019
  • 9. Hockman, S, Glembot T, Niebel K. Comparison of capnography derived respiratory rate alarm frequency using the SARA algorithm versus an established non-adaptive respiratory rate alarm management algorithm in bariatric surgical patients. Resp Care. Open Forum Abstract; December 2009.
Corporate Resources
Medical Surgical Portfolio
Additional Resources
Contact Us
Medtronic Limited

Building 9, Croxley Park

Hatters Lane

Watford, WD18 8WW

United Kingdom

©2025 Medtronic
EMEA-PM-2300089: 2024-03